Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

Abstract Introduction Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all-case post-marketing surveillance is ongoing to collect data in Japanese patients treated with idarucizumab who h...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Hidesaku Asakura, Teiichi Yamane, Yukako Ogi, Kaori Ochiai, Daisuke Nakayama
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Adis, Springer Healthcare 2020-03-01
Cyfres:	Cardiology and Therapy
Pynciau:	Anticoagulant Dabigatran Emergency surgery Hemorrhage Idarucizumab Japan
Mynediad Ar-lein:	https://doi.org/10.1007/s40119-020-00165-8
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!